August 15, 2024

June 25, 2024

May 22, 2024

January 24, 2024

July 25, 2023

May 18, 2023

May 3, 2023

April 3, 2023

December 8, 2022

September 19, 2022

May 11, 2022

April 25, 2022

February 7, 2022

January 25, 2022

January 7, 2022

December 3, 2021

September 23, 2021

August 18, 2021

June 30, 2021

June 23, 2021

June 16, 2021

June 1, 2021

May 5, 2021

April 28, 2021

March 2, 2021

February 18, 2021

February 18, 2021

October 1, 2020

August 21, 2020

August 19, 2020

August 14, 2020

July 9, 2020

June 15, 2020

May 27, 2020

April 28, 2020

April 23, 2020

March 12, 2020

March 12, 2020

February 28, 2020

February 11, 2020

February 10, 2020

January 10, 2020

January 6, 2020

January 6, 2020

November 18, 2019

November 15, 2019

November 13, 2019

October 30, 2019

October 22, 2019

October 22, 2019

October 11, 2019

October 4, 2019

September 30, 2019

September 18, 2019

August 20, 2019

August 20, 2019

July 16, 2019

June 18, 2019

June 13, 2019

June 11, 2019

May 15, 2019

May 7, 2019

April 30, 2019

April 30, 2019

April 15, 2019

April 9, 2019

March 28, 2019

March 18, 2019

February 27, 2019

February 5, 2019

January 30, 2019

January 8, 2019

November 19, 2018

November 13, 2018

November 13, 2018

October 25, 2018

October 25, 2018

October 22, 2018

July 9, 2018

July 09, 2018 — RESEARCH TRIANGLE PARK, N.C. (GLOBE NEWSWIRE) — G1 Therapeutics, Inc. (Nasdaq:GTHX), a clinical-stage oncology company, today announced appointments for two newly created executive leadership roles to support the company’s continued growth. John Demaree joins the company as Chief Commercial Officer and Stillman Hanson has been named General Counsel.

April 18, 2018

April 18, 2018 — CINCINNATI, OH — Standard Bariatrics, Inc., an innovator of bariatric surgical devices, has raised a Series A round of financing. RiverVest Venture Partners led the round with participation from Hatteras Venture Partners, Queen City Angels/QCA First Fund V, Emergent Medical Partners, Accelerant Fund and North Coast Angels. The size of the round is undisclosed.

March 20, 2018

March 20, 2018 — AUSTIN, TX (BUSINESS WIRE) — Elligo Health Research, which improves clinical trial access by engaging the 97 percent of physicians currently not offering clinical research to their patients, announced today $16 million in Series B funding led by Hatteras Venture Partners and Noro-Moseley Partners with participation from FS Healthcare LLC, Excelerate Health Ventures and all existing Series A investors including Shumway Capital.

March 13, 2018

March 07, 2018 — SAN FRANCISCO (PRWEB) — Wildflower Health today announced it has secured $8 million in capital investment to advance its mission of growing healthy families. The funding round was led by Health Enterprise Partners, a growth equity firm specializing in healthcare services and information technology whose investors include some of the largest health systems and health plans across the country.

March 7, 2018

March 07, 2018 — ALPHARETTA, Ga. (GLOBE NEWSWIRE) — Clearside Biomedical, Inc. (NASDAQ:CLSD), a late-stage clinical biopharmaceutical company developing first-in-class drug therapies to treat back-of-the-eye diseases, today announced the pricing of its underwritten public offering of 6,538,462 shares of its common stock at a price to the public of $13.00 per share.

March 7, 2018

March 07, 2018 — RESEARCH TRIANGLE PARK, N.C. (GLOBE NEWSWIRE) — G1 Therapeutics, Inc. (Nasdaq:GTHX), a clinical-stage oncology company, today announced the pricing of an underwritten public offering of 3,400,000 shares of its common stock at a public offering price of $29.50, for total gross proceeds of $100.3 million.

January 16, 2018

January 16, 2018 — BOSTON — Press Ganey today announced the acquisition of Bivarus, which offers real-time patient and caregiver insights through a patented, dynamic consumer feedback platform. The addition of Bivarus’s capabilities complements Press Ganey’s comprehensive suite of solutions designed to help clients improve the overall safety, quality and experience of care for consumers and achieve the goal of zero harm.

December 4, 2017

December 4, 2017 — TORONTO — Qvella, a leading molecular diagnostics company, today announced it has closed US$20 million in Series B financing. The funding round was co-led by Qvella’s existing investor syndicate—including RA Capital, Whitecap Venture Partners, Hatteras Ventures, and Sands Capital—and new strategic investor bioMérieux, a world leader in the field of in vitro diagnostics.

November 28, 2017

Nov. 28, 2017 (GLOBE NEWSWIRE) — RESEARCH TRIANGLE PARK, N.C. — G1 Therapeutics, Inc. (NASDAQ:GTHX), a clinical-stage oncology company, today announced a clinical trial collaboration with AstraZeneca to evaluate AstraZeneca’s epidermal growth factor receptor (EGFR) tyrosine kinase inhibitor (TKI) Tagrisso® (osimertinib) in combination with G1’s oral CDK4/6 inhibitor G1T38 for the treatment of EGFR mutation-positive non-small cell lung cancer (NSCLC).

October 31, 2017

Oct. 31, 2017 (MARKETWIRED) — DURHAM, NC — Ribometrix, Inc., a biotech company dedicated to discovering and developing small molecule modulators of RNA to treat disease, has raised $7.5 million in seed capital.

September 19, 2017

Sept. 19, 2017 — DURHAM, NC — Hatteras Venture Partners today announced it has named Sir Andrew Witty a Venture Partner. Mr. Witty will primarily focus on the strategic positioning of Hatteras and its portfolio companies in the ever-changing global health care industry. In addition, Mr. Witty will provide leadership counsel to Hatteras’ portfolio companies.

September 18, 2017

Sept. 18, 2017 — CAMBRIDGE, MA — Rodin Therapeutics, a biotechnology company discovering and developing novel therapeutics to boost synaptic resilience, announced today significant progress in advancing the company’s strategic vision, including the completion of a $27 million financing round, and the addition of three new members to its Board of Directors.

August 4, 2017

Aug. 3, 2017 (PRNEWSWIRE) — BOSTON — Veritas Genetics, the genome company, announces the acquisition of Boston-based Curoverse, the preeminent computing and bioinformatics company behind the Personal Genome Project (PGP) at Harvard Medical School, and creator of the open-source platform Arvados. Curoverse software is used by industry leaders such as the Wellcome Trust Sanger Institute to manage, process and share petabytes of genomic and biomedical data as well as facilitate AI and machine learning.

June 7, 2017

June 7, 2017 (PRNEWSWIRE) —ANN ARBOR, MI  — HistoSonics, Inc., a venture-backed medical device company developing a new image-guided, robotically assisted, platform therapy that is non-invasive and non-thermal, announced two significant developments today.

May 30, 2017

May 30, 2017 (GLOBE NEWSWIRE) — RESEARCH TRIANGLE PARK, N.C. — G1 Therapeutics, Inc. (NASDAQ:GTHX), a clinical-stage oncology company, today announced that Phase 1b data from the ongoing Phase 1b/2a study of its lead CDK4/6 inhibitor trilaciclib as a first-line combination treatment in patients with extensive stage small-cell lung cancer (SCLC) will be presented in a poster session at the 2017 American Society of Clinical Oncology (ASCO) Annual Meeting, to be held June 2 – 6 at McCormick Place in Chicago.

May 16, 2017

May 16, 2017 (GLOBE NEWSWIRE) — RESEARCH TRIANGLE PARK, N.C. — G1 Therapeutics, Inc., a clinical-stage oncology company, today announced the pricing of its initial public offering of 7,000,000 shares of common stock at a public offering price of $15.00 per share for aggregate gross proceeds of $105,000,000.

April 18, 2017

April 18, 2017 — DUBLIN IRELAND AND DURHAM, N.C., USA — NeuroTronik Limited and NeuroTronik, Inc. today announced closing on a $23.1 million Series B Preferred Stock Financing, tranched in line with project plan milestones. The funding was led by Boston Scientific Group, plc. Other major investors include Hatteras Venture Partners, Synergy Life Science Partners, Lord Baltimore Investment Partners, Mountain Group Capital, and Sovereign’s Capital. The investor group also includes other financial and industry participants.

March 24, 2017

March 21, 2017  — DURHAM, N.C. — Bivarus, a patient-centered analytics company working with healthcare organizations to measure and analyze the patient experience and employee engagement, announced today it raised $4 million in a Series B from existing investors. Hatteras Venture Partners led this latest financing round. Other participants in the round include Excelerate Health Ventures, Nashville-based NueCura Partners and Boston Millennia Partners.

February 28, 2017

February 28, 2017 – DURHAM, NC – As announced previously by former Governor McCrory, Hatteras Venture Partners was selected by the State of North Carolina as the manager of the Venture Capital Multiplier Fund, LP (VCMF). The VCMF has $60 million in capital. A portion of the VCMF has been committed to the latest Hatteras venture capital fund, Hatteras Venture Partners V, LP (HVP V).

January 18, 2017

RESEARCH TRIANGLE PARK, N.C., January 6, 2017, – Viamet Pharmaceuticals, Inc. today reported positive efficacy and safety results from REVIVE (Recurrent Vulvovaginal Candidiasis Inhibition: an Oral VT-1161 Tablet Evaluation), a Phase 2b clinical trial of VT-1161 for the treatment of recurrent vulvovaginal candidiasis, or RVVC. RVVC is defined as three or more episodes of acute vulvovaginal candidiasis, or AVVC (commonly referred to as a vaginal yeast infection), in a 12-month period. VT-1161, the company’s lead product candidate, is a highly potent and selective, orally available inhibitor of fungal CYP51.

January 6, 2017

RESEARCH TRIANGLE PARK, N.C., January 6, 2017, – Viamet Pharmaceuticals, Inc. today reported positive results from RENOVATE (REstoring Nail; an Oral VT-1161 Tablet Evaluation), its Phase 2b clinical trial of VT-1161 in onychomycosis of the large toenail. Onychomycosis is a chronic fungal infection involving the nail, nail bed, and surrounding tissues. VT-1161, the company’s lead product candidate, is a highly potent and selective orally available inhibitor of fungal CYP51.

January 6, 2017

RESEARCH TRIANGLE PARK, N.C., January 6, 2017, – Viamet Pharmaceuticals, Inc. today reported positive efficacy and safety results from REVIVE (Recurrent Vulvovaginal Candidiasis Inhibition: an Oral VT-1161 Tablet Evaluation), a Phase 2b clinical trial of VT-1161 for the treatment of recurrent vulvovaginal candidiasis, or RVVC. RVVC is defined as three or more episodes of acute vulvovaginal candidiasis, or AVVC (commonly referred to as a vaginal yeast infection), in a 12-month period. VT-1161, the company’s lead product candidate, is a highly potent and selective, orally available inhibitor of fungal CYP51.

January 5, 2017

DURHAM N.C., January 5, 2017  – Hatteras Venture Partners announced today the final closing of Hatteras Venture Partners V (HVP V) with over $150 million in total capital. Hatteras will continue its strategy of building great companies in the human medicine life sciences by investing at the seed and early stage. Like HVP IV, the firm will allocate a portion of HVP V to Hatteras Discovery to expand its successful model of company formation.

December 5, 2016

RESEARCH TRIANGLE PARK, N.C., Dec. 05, 2016 (GLOBE NEWSWIRE) — G1 Therapeutics, Inc. a clinical-stage oncology company, announced today a clinical trial collaboration with Genentech, a member of the Roche Group. A Phase 2 clinical trial is expected to begin in the first half of 2017 and will evaluate the combination of Genentech’s immune checkpoint, anti-PD-L1 antibody Tecentriq® (atezolizumab) with G1’s CDK4/6 inhibitor trilaciclib (G1T28) as a first-line treatment for patients with small-cell lung cancer (SCLC) receiving chemotherapy.

October 4, 2016

CARY, N.C.– Medfusion, a leading provider of patient experience solutions, today announced that GE Healthcare has named the company as the inaugural member of its Centricity™ Partner Program. GE Healthcare’s Centricity™ Partner Program recognizes Centricity software and services partners and enables them to collaboratively test software and services with GE Healthcare solutions.

September 14, 2016

Ann Arbor, MI – September 13, 2016 – HistoSonics, Inc. (http://www.histosonics.com ) (the “Company”) announced today that noted radiologist and tumor ablation expert Fred Lee, Jr., MD, has joined the Company as Senior Medical Advisor and Board member to advance HistoSonics’ innovative tissue-destruction technology in liver cancer and other solid tumor applications.

August 23, 2016

Durham, NC; August 18, 2016 – Spyryx Biosciences, Inc., a clinical-stage biopharmaceutical company developing novel therapeutics for respiratory diseases, including cystic fibrosis (CF), announced today that Dr. Alistair Wheeler has joined the company in the newly created position of chief medical officer.

July 27, 2016

ALPHARETTA, Ga., July 26, 2016 (GLOBE NEWSWIRE) — Clearside Biomedical, Inc. (NASDAQ:CLSD), a late-stage clinical biopharmaceutical company developing first-in-class drug therapies to treat blinding diseases of the eye, today reports additional top-line data from its Phase 2 clinical trial (TANZANITE).

June 22, 2016

Redwood City, CA – June 21, 2016 – Graybug Vision, Inc., a venture-stage pharmaceutical company committed to developing potentially transformative therapies for ocular diseases including wet age-related macular degeneration (AMD) and glaucoma, today announced that two prominent industry executives have joined its management team. 

June 2, 2016

ALPHARETTA, Ga., June 01, 2016 (GLOBE NEWSWIRE) — Clearside Biomedical, Inc. (NASDAQ:CLSD), a late-stage clinical biopharmaceutical company developing first-in-class drug therapies to treat blinding diseases of the eye, today announced the pricing of its initial public offering of 7,200,000 shares of its common stock at a public offering price of .00 per share. 

May 11, 2016

RESEARCH TRIANGLE PARK, N.C., May 11, 2016 (GLOBE NEWSWIRE) — G1 Therapeutics, Inc., a clinical-stage oncology company, announced today the completion of a $47 million Series C financing led by new investor Cormorant Asset Management. Additional new investors include Aju IB Investment, Cowen Private Investments, Franklin Templeton Investments and Rock Springs Capital.

May 6, 2016

REDWOOD CITY, CA–(Marketwired – May 2, 2016) – Graybug Vision, a venture-stage pharmaceutical company committed to developing potentially transformative therapies for ocular diseases including wet age-related macular degeneration (AMD) and glaucoma, today announced the closing of a $44.5 million Series B financing.

May 6, 2016

Wyoming is improving its birth outcomes one downloader at a time. An interactive mobile app—Due Date Plus—that the state Medicaid office developed for pregnant women is redefining prenatal education and transforming how Medicaid meets the needs of its pregnant population.

April 26, 2016

Alpharetta, GA (April 26, 2016) – Clearside Biomedical, Inc. today announced that its Phase 2 clinical trial evaluating concomitant administration of suprachoroidal ZUPRATA™, Clearside’s proprietary form of triamcinolone acetonide, together with intravitreal aflibercept (EYLEA®), for the treatment of macular edema associated with retinal vein occlusion (RVO), achieved its primary endpoint. 

April 25, 2016

CARY, N.C.–(BUSINESS WIRE)–The CEO Roundtable on Cancer has accredited Hatteras Venture Partners, an early-stage venture capital investment company in Durham, N.C., with the CEO Cancer Gold StandardTM recognizing its efforts to reduce the risk of cancer for its employees and covered family members.

March 24, 2016

DURHAM, N.C. (Business Wire) March 23, 2016 – Bivarus, a patient-centered analytics company working with healthcare organizations to measure and analyze the patient experience, announced today it raised $2 million in its oversubscribed round of funding. This latest financing was co-led by new investor Hatteras Venture Partners and existing investor Excelerate Health Ventures.

March 7, 2016

Each year as a part of its annual Women In Business Awards, Triangle Business Journal selects a female executive who has impacted the Triangle community not only with the work she’s accomplished throughout her career, but also her dedication to the community’s greater good. We call it the Lifetime Achievement Award.

March 2, 2016

March 2, 2016 – Chapel Hill and Durham, NC – Hatteras Venture Partners and Carolina Research Ventures, LLC (CRV) announced today the selection of Hatteras as the manager of CRV’s investment fund. CRV is an early stage venture investment fund created to support companies sourced at the University of North Carolina at Chapel Hill.

March 2, 2016

CARY, N.C.–(BUSINESS WIRE)–Medfusion, a leading provider of patient experience management (PXM) solutions, today announced it will debut the latest version of its mobile app, Medfusion Plus, at the Healthcare Information and Management Systems Society 2016 Annual Conference & Exhibition (HIMSS16). This latest product development supports the company’s initiative to empower patients by facilitating access to and transparency of their own health data through mobile devices.

February 5, 2016

At our entrepreneurial support organization, the Council for Entrepreneurial Development (CED), we often joke about adhering to the proper dress and catering code for our networking events: jeans and beer for tech; suits, wine and cocktails for life sciences.

January 8, 2016

ALPHARETTA, Ga.–(BUSINESS WIRE)–Clearside Biomedical, Inc., a late-stage clinical biopharmaceutical company developing innovative first-in-class drug therapies to treat blinding diseases of the eye, today announced positive results from the company’s Phase 2 clinical trial of CLS-TA, Clearside’s proprietary form of triamcinolone acetonide, using suprachoroidal space (SCS™) drug administration for the treatment of macular edema associated with non-infectious uveitis.

December 17, 2015

BOSTON, Dec. 16, 2015 /PRNewswire/ — ORIG3N Inc., a biotechnology company developing breakthrough treatments for rare and genetically inherited diseases and a pioneer in regenerative medicine announces the close of a $12.5 million Series A financing from an investor syndicate co-led by Hatteras Venture Partners and Syno Capital.

December 17, 2015

ALPHARETTA, Ga.–(BUSINESS WIRE)–Clearside Biomedical, Inc., a clinical-stage biopharmaceutical company developing innovative first-in-class drug therapies to treat blinding diseases of the eye, today announced the closing of a $20 million Series C financing.

December 4, 2015

When I was a senior in college, my career goals were fairly simple. I wanted to work for a company that was doing something I cared deeply about. So, when I started actually looking for jobs, I limited my search to non-profits, because, well, in my mind: non-profits = world changers, for-profits = EVIL EMPIRES OF EVIL.

October 29, 2015

It’s been more than a decade in the making, but Qvella is close to the holy grail of diagnostics–a compact, inexpensive pathogen analyzer that identifies the precise culprit in only 30 minutes. The idea is to enable better infection treatment faster as well as to minimize the overuse of antibiotics, which leads to the development of resistance.

September 1, 2015

CARY, N.C., Sept. 1, 2015 /PRNewswire/ — Medfusion, Inc., a patient engagement platform dedicated to facilitating the relationship between doctors and patients, today announced a $3 million investment from two Durham, N.C.-based venture capital firms.

August 25, 2015

August 24, 2015 – Durham, NC – Hatteras Venture Partners announced today the first closing of Hatteras Venture Partners V (HVP V) with more than $90 million in subscriptions towards a final fund target of $150 million. In addition, Hatteras has entered a partnership with Malin Corporation PLC to bolster the firm’s strategic partnering capacity to grow portfolio companies from the seed stage to maturity.

August 11, 2015

RESEARCH TRIANGLE PARK, NC, August 11, 2015 – G1 Therapeutics, Inc., a clinical-stage oncology company, announced today that it has initiated two Phase 1b/2a trials of the CDK4/6 inhibitor G1T28 in patients with small-cell lung cancer (SCLC). G1T28 is an intravenous (IV) therapy being studied as a bone marrow and immune system chemoprotectant in patients with SCLC who are receiving chemotherapy.

August 6, 2015

IRVINE, California & BALTIMORE, Maryland – (BUSINESS WIRE)–Aerie Pharmaceuticals, Inc. (NASDAQ:AERI), a clinical-stage pharmaceutical company focused on the discovery, development and commercialization of first-in-class therapies for the treatment of patients with glaucoma and other diseases of the eye, and GrayBug, Inc., a venture-stage pharmaceutical company developing microparticle controlled release drug delivery technologies for the treatment of ocular diseases including wet age-related macular degeneration (AMD) and glaucoma, today announced a research collaboration and license agreement to deliver certain of Aerie’s preclinical product candidates to both the front and back of the eye using GrayBug’s proprietary technology.

June 30, 2015

SAN FRANCISCO, June 25, 2015 — Wildflower Health, maker of mobile maternity program Due Date Plus (www.wildflowerhealth.com/programs), today announced a $5 million investment in the company to facilitate its strategic expansion. New investors Easton Capital and Hatteras Venture Partners led the funding round with participation by existing investors Cambia Health Solutions and HealthTechCapital.

May 19, 2015

BOSTON, May 19, 2015 /PRNewswire/ — ORIG3N, Inc., a pioneer in regenerative medicine and provider of induced pluripotent stem cell (iPSC) storage, called LifeCapsule (www.capsule.life), today announced a strategic collaboration order tramadol online c.o.d with Laboratory Corporation of America® Holdings (LabCorp®) (LH).

May 18, 2015

NASHVILLE, Tenn.–(BUSINESS WIRE)–NuSirt Biopharma, a company dedicated to improving the lives of those with chronic metabolic diseases, announced it has raised $6 million in Series C financing, of which $2 million has been funded. Hatteras Venture Partners was joined by existing stockholders, including Mountain Group Partners and TriStar Technology Ventures.

May 7, 2015

Research Triangle Park, NC, May 7, 2015 – Spyryx Biosciences, Inc., a privately-held biopharmaceutical company developing novel therapeutics for respiratory diseases, including cystic fibrosis (CF) and chronic obstructive pulmonary disorder (COPD), announced today that it has secured $18 million in Series A venture capital financing from Canaan Partners, Hatteras Venture Partners and 5AM Ventures.

May 4, 2015

Alpharetta, GA and Emeryville, CA (May 4, 2015) – Clearside Biomedical, Inc., a clinical-stage biopharmaceutical company developing first-in-class drug therapies to treat blinding diseases of the eye, and Santen Inc., a wholly owned subsidiary of Santen Pharmaceuticals Co., Ltd., today announced the expansion of their research collaboration to include the field of glaucoma.

April 29, 2015

PHILADELPHIA, Penn., April28, 2015 – Spark Therapeutics, Inc. (NASDAQ: ONCE) and Clearside Biomedical, Inc. announced today that they have entered into an option agreement under which Spark acquired exclusive rights to license Clearside’s microinjector technology to deliver gene therapies to the back of the eye. Under the agreement, the companies will explore the feasibility of using Clearside’s microinjector technology to deliver viral vectors to the choroid and the retina through the suprachoroidal space (SCS).

April 20, 2015

RALEIGH, N.C., April 17, 2015 /PRNewswire/ — Contego Medical, the first and only provider of the Integrated Embolic Protection™ filter platform for angioplasty balloon and stent delivery catheters, announces the completion of a $5.6 million Series B financing round led by Hatteras Venture Partners, an early stage venture firm with a focus on medical devices, biopharmaceuticals, diagnostics and related opportunities in human medicine. The round also included Mountain Group Partners, Lookout Capital and Medical Mutual.

March 17, 2015

BALTIMORE (March 17, 2015) – GrayBug Inc., a privately held pharmaceutical company developing drug delivery therapies and sustained-release compounds for the treatment of eye diseases, today announced that its co-founder and Chief Scientific Officer Dr. Justin Hanes will deliver the keynote presentation, titled “The Dawn of Nanotechnology in Ocular Therapeutics” at the 7th Ocular Diseases Drug Discovery Conference at the Westin San Diego on Thursday, March 19 at 8:00 a.m.

March 12, 2015

Malvern, PA, March 12, 2015 — PhaseBio Pharmaceuticals, Inc., a leading company in the field of biopolymer-based drugs and focused on developing treatments for metabolic and specialty cardiopulmonary disorders, today announced that it has closed a $40 million Series C financing round led by AstraZeneca.

March 10, 2015

BALTIMORE (March 10, 2015) – GrayBug, Inc., a privately held pharmaceutical company developing drug delivery therapies and sustained-release compounds for the treatment of eye diseases, today announced the closing of a $1.74 million Series A2 financing round led by new investor Hatteras Venture Partners and existing investor Maryland Venture Fund.

February 13, 2015

BOSTON – February 5, 2015 – ORIG3N, Inc., a pioneer in regenerative medicine and provider ofpluripotent stem cell storage, has raised $3.1 million in funding from an investor syndicate that includes Hatteras Venture Partners, Harris & Harris Group, KTB and Mountain Group Capital.

February 9, 2015

CAMBRIDGE, Mass. — Feb. 3, 2015 — Lysosomal Therapeutics Inc. (LTI), a company leveraging its expertise in lysosomal biology to develop novel small molecules for use in the treatment of neurodegenerative diseases, announced today it has raised $20 million in Series A financing.

February 5, 2015

RESEARCH TRIANGLE PARK, N.C., Feb. 5, 2015 (GLOBE NEWSWIRE) — G1 Therapeutics, Inc., a clinical-stage pharmaceutical company developing small-molecule therapies to address significant unmet needs in oncology, today announced the completion of a $33 million Series B financing round. Lead investors Eshelman Ventures and RA Capital Management were joined by new investors Lumira Capital and Boxer Capital of Tavistock Life Sciences, as well as the company’s existing investors Hatteras Venture Partners, MedImmune Ventures, and Mountain Group Capital.

February 2, 2015

RESEARCH TRIANGLE PARK, N.C., Feb. 2, 2015 (GLOBE NEWSWIRE) — G1 Therapeutics, Inc., a clinical-stage pharmaceutical company developing small-molecule therapies to address significant unmet needs in oncology, today announced that Chief Executive Officer Mark Velleca, MD, PhD, will provide a corporate overview at the 17th Annual BIO CEO & Investor Conference. The presentation will take place on Monday, February 9 at 9:45 a.m. ET at the Waldorf Astoria in New York City.

October 15, 2014

Alpharetta, Ga.–(BUSINESS WIRE)–Clearside Biomedical, Inc. today announced the eight-week ongoing observations in patients with non-infectious uveitis.

September 18, 2014

ALPHARETTA, Ga.–(BUSINESS WIRE)–Clearside order tramadol online mastercard Biomedical, Inc., today announced the closing of a $16 million Series B financing. The financing included new investor RusnanoMedInvest (RMI) and existing investors Hatteras Venture Partners, Santen Pharmaceuticals Co. Ltd., Mountain Group Capital and Georgia Research Alliance Venture Fund.

September 18, 2014

RESEARCH PARK TRIANGLE, NC, September 10, 2014 – G1 Therapeutics, Inc., a privately held, clinical-stage pharmaceutical company, today announced the initiation of a Phase 1 clinical trial of G1T28-1, a highly potent and selective CDK4/6 inhibitor with broad potential in multiple oncology indications.

September 4, 2014

ALPHARETTA, Ga. – (BUSINESS WIRE) – Clearside Biomedical, Inc., today announced the closing of a $16 million Series B financing. The financing included new investor RusnanoMedInvest (RMI) and existing investors Hatteras Venture Partners, Santen Pharmaceuticals Co. Ltd., Mountain Group Capital and Georgia Research Alliance Venture Fund.

August 19, 2014

LAWRENCEVILLE, N.J., Aug. 19, 2014 (GLOBE NEWSWIRE) — via PRWEB – Edison Partners proudly announced today leading a $9 million growth financing of Clinverse, Inc. Based in Durham, NC, Clinverse is an emerging leader in clinical trial finance, automating millions of dollars in financial transactions for clinical trials across the globe. Edison’s $5 million investment will accelerate the company’s product roadmap, bolster infrastructure, and expand sales and marketing. Co-investors include Hatteras Venture Partners.

June 17, 2014

RESEARCH PARK TRIANGLE, NC, June 17, 2014 – G1 Therapeutics, Inc., a privately held pharmaceutical company that focuses on the discovery and development of novel small molecules for use in cancer therapy and biodefense applications, today announced that Raj Malik, MD, has joined the company as Chief Medical Officer and Greg Mossinghoff has been named Chief Business Officer.

May 20, 2014

Research Triangle Park, NC, May 20, 2014 – G1 Therapeutics, Inc., a privately held pharmaceutical company that focuses on the discovery and development of novel small molecules for use in cancer therapy and biodefense applications, today announced the appointment of Mark Velleca, M.D., Ph.D. as chief executive officer, effective immediately.

May 14, 2014

Lysosomal Therapeutics Inc. (LTI), a company leveraging its expertise in lysosomal biology to develop novel small molecules for use in the treatment of neurodegenerative diseases, announced today it has raised $4.8 million in seed funding.

April 21, 2014

On April 9, Morrisville’s Clinipace Worldwide announced a partnership with Massachusetts pharmaceutical company Karyopharm Therapeutics (Nasdaq: KPTI), a development-stage company working primarily on cancer treatments. In this arrangement, Karyopharm chose Clinipace as a “preferred provider” in which Clinipace will manage several clinical programs, including oncology and wound healing.

March 12, 2014

MORRISVILLE, N.C. (Business Wire) March 11, 2014 – Clinipace Worldwide, a global digital contract research organization (dCRO), announced today the closing of its merger with Choice Pharma, a Pan-Asian contract research organization. Bringing these organizations together strengthens Clinipace Worldwide’s operational and therapeutic expertise in Asia, a region in high demand by Clinipace’s clients.

January 7, 2014

Chapel Hill, NC, January 7, 2013– G1 Therapeutics, Inc. today announced that it has named Seth Rudnick, M.D. as executive chairman of its board of directors, effective immediately. Dr. Rudnick has been serving as the chair of G1’s Scientific Advisory Board for the past year and will continue in this role with the company.

December 19, 2013

Biomedical big data is receiving a new platform.Curoverse announced Wednesday the Harvard-spun startup has raised $1.5 million to accelerate the development of Arvados, its open-source computational storage platform currently being used at the Harvard Personal Genome Project andHarvard Medical School.

November 21, 2013

The UNC Kenan-Flagler Distinguished Alumni in Healthcare is given out each year at the annual UNC Kenan-Flagler Healthcare Conference to recognize a KFBS alumnus with extraordinary career accomplishments in the healthcare industry. 

November 14, 2013

Chapel Hill, NC, November 1, 2013 – G1 Therapeutics, Inc. today announced that it has been selected as a MAIN/Stage presenter at the 2013 Southeast BIO Investor & Partnering Forum to be held November 6-7 at the Jefferson Hotel in Richmond, Virginia. Christy Shaffer, Ph.D., Executive Chair of G1’s Board of Directors, will present to the audience of potential investors and partners on the afternoon of November 6. Jay Strum, Ph.D., President of G1, will also be in attendance.

October 16, 2013

Chapel Hill, NC, October 16, 2013 – G1 Therapeutics, Inc. today announced that it has raised a Series A financing of $12.5M that will enable the advancement of its lead clinical candidate through the filing of an Investigational New Drug application (IND) and initial clinical testing. The financing was led by MedImmune Ventures. Co-investors include Hatteras Venture Partners and Mountain Group Capital. 

August 12, 2013

Did you ever meet someone and think-WOW, they are really making a difference-this is IMPACT! Christy Shaffer is one of these individuals. In this age of convergence, IMPACT is not only a reality, but it is a necessary skill for us as individuals, members of our organizations and the entire community. Join WIB and learn what IMPACT is, and how we can develop the skills and attitudes to make a real difference.

July 12, 2013

Using the genetic properties of tumors to classify them more specifically and determine whether they may respond to anti-angiogenic drugs has netted a two-year-old diagnostics firm a .5 million round.

June 24, 2013

When Jeff Williams was thinking about starting a pharmaceutical services company a decade ago, his first impulse was to locate the business along the coast of Florida so that, during his off hours, he could indulge his passion for the beach.

June 13, 2013

Medical device startup NeuroTronik, which was spun out of a Chapel Hill business accelerator just 11 months ago, has raised its first round of outside funding: $13.1 million that is earmarked for continued development of a system to treat heart failure.

May 6, 2013

TiE Atlanta’s marquee event, TiECON Southeast 2013, celebrated TiE Atlanta’s 15th Anniversary.  

March 1, 2013

Former Glaxo chair Robert Ingram won the Life Science Leadership Award Thursday afternoon, a presentation that was part of the 2013 CED Life Sciences Conference at the Raleigh Convention Center.

February 11, 2013

February 6, 2013 – Clinipace Worldwide, a digital clinical research organization (dCRO), announced today announced that the company has been listed at No. 36 on FORBES annual ranking of America’s Most Promising Companies — a list of 100 privately held, high-growth companies with bright futures. Clinipace is a portfolio company of Hatteras Venture Partners III.

January 31, 2013

January 31, 2013— Santen Inc., a wholly owned subsidiary of Santen Pharmaceuticals Co., Ltd. (Osaka, Japan, Ticker Code 4536JP), and Clearside Biomedical, Inc. announced today that Santen Ltd., the parent company of Santen Inc., has made an investment in Clearside Biomedical Inc. and has also entered into a research collaboration agreement for posterior ocular diseases. 

January 7, 2013

WASHINGTON – Hatteras Venture Partners of Durham, N.C. is the first licensee in the Early Stage Innovation Funds initiative, a part of the U.S. Small Business Administration’s (SBA) Small Business Investment Company (SBIC) capital investment program.

January 7, 2013

Durham, NC – Hatteras Venture Partners announced today the final closing of Hatteras Venture Partners IV (HVP IV) with $125 million in total capital. As a part of the final closing, HVP IV established a subsidiary fund, HVP IV SBIC, that is the first licensee of the US Small Business Administration’s (SBA) newly established Early Stage SBIC Program.

November 6, 2012

ATLANTA, GA – Clearside Biomedical, Inc., a privately held company specializing in the research and development of ophthalmic pharmaceuticals, today announced the successful dosing of patients in a safety and tolerability clinical study using its proprietary ocular microinjection platform to deliver therapeutics to treat retinal disease.

July 16, 2012

STONY BROOK, NY – (MARKETWIRE via COMTEX) – Coferon Inc., a privately held, New York-based biotechnology company, today announced that it has closed on a $12 million Series B financing round led by a trio of new venture investors: Hatteras Venture Partners of Durham, N.C.; MedImmune Ventures of Gaithersburg, MD (the corporate venture arm of AstraZeneca Ltd); and Ascent Biomedical Ventures of New York, N.Y.

May 7, 2012

RALEIGH, NC – (BUSINESS WIRE) – Clinverse, Inc., the global cloud-based ecommerce platform provider for clinical buy legit tramadol online trials, announced today that it has closed a $3.8 million Series B round of funding led by Hatteras Venture Partners of Durham, NC. Vital Financial of Bethesda, MD, also participated in this funding round.

January 5, 2012

ATLANTA and DURHAM – (Business Wire) – Ophthalmic startup Clearside Biomedical, Inc. and Hatteras Venture Partners announce today that they have launched the company with a $4,000,000 Series A venture financing to fund the initial development of Clearside Biomedical’s ocular microinjection platform and initial clinical testing of Clearside Biomedical’s lead product for Macular Edema and Retinal Vein Occlusion.

November 15, 2011

MALVERN, PA – (Business Wire) – PhaseBio Pharmaceuticals, Inc. announced today positive results from its Phase I/IIa single and multiple ascending dose clinical study with Glymera™, a recombinant glucagon-like peptide-1 (GLP-1) analogue for the treatment of hyperglycemia in patients with type 2 diabetes. In a dose dependent manner, Glymera™ demonstrated highly statistically significant reductions in fasting glucose glycemic load following meal tolerance testing, and average daily glucose measured through continuous glucose monitoring following 4 weeks of dosing.

September 27, 2011

MORRISVILLE, N.C. (Business Wire) – Clinipace Worldwide, a global digital clinical research organization (dCRO) that has pioneered technology-amplified contract research services, announced today it has closed a $15M Series C round of funding led by Morgan Stanley Expansion Capital of San Francisco, CA. Existing investors, including Hatteras Venture Partners of Durham, NC, and Brook Private Equity Advisors of Boston, MA, also participated in this most recent round of funding.

August 16, 2011

DURHAM, NC – Hatteras Venture Partners announced today the first closing of Hatteras Venture Partners IV (HVP IV) with $74 million in subscriptions towards a final fund target of $125 million. With HVP IV, Hatteras has formally launched “Hatteras Discovery,” an allocation of the fund focused on seed-stage companies and projects in the field of human medicine and life sciences.

March 24, 2011

WALTHAM, MA – PerkinElmer, Inc. (NYSE: PKI), a global leader focused on the health and safety of people and the environment, today announced that it has signed a definitive agreement to acquire CambridgeSoft Corporation, and has completed the purchase of ArtusLabs, Inc. These acquisitions will enhance the Company’s focus on knowledge management in laboratory settings by expanding its informatics and software offerings, enabling customers to rapidly access and share enterprise-wide data for faster, more informed scientific decisions.

March 11, 2011

November 2, 2010

September 20, 2010

August 24, 2010

February 23, 2010

January 4, 2010

Ann Arbor, MI – HistoSonics, Inc. today announced it has secured $11 million in a Series A financing led by Venture Investors of Ann Arbor, Michigan and Madison, Wisconsin. Venture Investors worked closely with Fletcher Spaght Ventures, Hatteras Venture Partners, Early Stage Partners, and TGap Ventures to assemble an outstanding investment syndicate.

November 9, 2009

Morrisville, NC – Clinipace, global technology-driven clinical research organization (CRO), announced today that is has closed its acquisition of Worldwide Clinical Research, Inc. (WWCR), a Midwest-based CRO specializing in the management of clinical studies for biotechnology and pharmaceutical companies. With the acquisition, Clinipace has changed its name to Clinipace Worldwide, Inc.

October 8, 2009

RTP, NC – Hatteras Venture Partners announced today that the recent sales of B.R.A.H.M.S. Holdings GmbH to Thermo Fisher Scientific for $470 million and ESBATech AG to Alcon, Inc. for $150 million upfront plus $439 million in clinical milestone payments has resulted in a full return of paid-in capital for Hatteras Venture Partners II, LP (HVP II, formerly Hatteras BioCapital Fund, LP). With this return of capital and the remaining thirteen investments in the fund, HVP II is one of the best performing venture capital funds in its class, as compared to the benchmarks for 2004 venture capital funds.

August 31, 2009

WSJ.com – Capital efficiency is key for venture-backed start-ups, especially those health care companies engaging in costly clinical trials. SpineAlign Medical Inc., which has launched a medical device in Europe on just $13.6 million, shows that a lot can be done with relatively little capital. SpineAlign, which is developing a treatment for vertebral-compression fractures that commonly occur in osteoporosis patients, has kept outlays low by minimizing fixed costs, contracting out many services and keeping headcount low.

August 14, 2009

Wayne, PA – Embrella Cardiovascular, Inc., a private company developing the next generation of embolic order tramadol online overnight shipping protection devices for use during coronary procedures, today announced the final closing of its Series B financing round, raising a total of $6.7 million in new capital.

July 23, 2009

San Jose, CA – SpineAlign Medical, Inc. (formerly SpineWorks Medical, Inc.) announced today the successful treatment of the first patient in its FDA Investigational Device Exemption (IDE) feasibility study. The SpineAlign System is designed for the treatment of vertebral compression fractures and features an innovative nitinol implant designed to achieve vertebral body reconstruction via a transpedicular, minimally-invasive approach.

July 7, 2009

Research Triangle Park, NC – Viamet Pharmaceuticals, Inc. announced today that it has secured $18 million in a Series B financing to accelerate the development of its novel metalloenzyme inhibitors and to advance its Metallophile™ Technology platform. The proprietary Metallophile™ Technology is based on Viamet’s world-class expertise in bioinorganic chemistry and metalloenzymes and allows Viamet to rapidly and cost-effectively generate “best-in-class”, novel compounds by optimizing the metal-binding component of existing metalloenzyme inhibitors. The investment was led by the Novartis Option Fund and Lilly Ventures and also included Viamet’s existing investors Intersouth Partners, Hatteras Venture Partners, Lurie Investment Fund, and Astellas Venture Management. As part of the closing of the financing, Lauren Silverman, Ph.D., Managing Director of the Novartis Option Fund and Ed Torres, Managing Director, Lilly Ventures, have joined Viamet’s board of directors.

March 11, 2009

Nashville, TN – Pathfinder, a medical device company with first to market products for “Surgical GPS” of the abdomen, announced that it has hired Skip Goode as President and CEO effective immediately. As head of Sales for leading edge companies including Medtronic Surgical Navigation, Accuray, and EndoGastric Solutions, Mr. Goode played a pioneering role in key product launches and sales efforts for innovative capital equipment and disposable tools in the surgical oncology field. Mr. Goode takes the helm in advance of the AHPBA conference where Pathfinder will launch its two FDA-cleared products for pre-operative planning and intra-operative navigation of liver surgery.

October 30, 2008

Nashville, TN – Pathfinder Therapeutics, Inc. (PTI), a medical device company focused on the development of “surgical GPS” systems for the abdomen, announced that it has closed on a $5.2 million Series A financing round led by Hatteras Venture Partners of Research Triangle Park, NC. Other investors included Florida Gulfshore Capital, Clayton & Associates, Nashville Capital Network, Lumira, and Vanderbilt University. Concurrent with the financing, Clay Thorp and Bob Morff, PhD, from Hatteras Venture Partners and Richard Molloy from Florida Gulfshore Capital have joined the Board of Pathfinder, and Bob will serve as interim CEO.

October 9, 2008

Morrisville, NC – Phase Bioscience, Inc., a development stage biopharmaceutical company, announced today that Dr. Craig Rosen has joined the company as Executive Chairman of the Board, effective immediately.

July 15, 2008

San Jose, CA – SpineWorks Medical, Inc. announced today that it received CE-Mark authorization for commercialization of its SpineAlign™ Vertebral Body Replacement (VBR) System in the European Union and all countries recognizing the CE-Mark. The SpineAlign VBR is SpineWorks Medical’s first approved product that was designed for a transpedicular, minimally-invasive approach to vertebral body reconstruction and anterior spinal column support.

May 20, 2008

Durham, NC – Hatteras Venture Partners announced today the establishment of its Scientific Advisory Board (SAB). The Board of internationally renowned scientists and industry experts is focused on helping Hatteras identify trends and opportunities in the fields of biopharmaceuticals, medical devices, diagnostics, and related areas of life science innovation.

April 15, 2008

Research Triangle Park, NC – Phase Bioscience, Inc., a development stage biotechnology company, announced today the appointment of Christopher Prior, Ph.D. as Chief Executive Officer and Member of the Board of Directors.

January 17, 2008

Research Triangle Park, NC – Clinipace, a clinical research software company based in the Research Triangle Park, announced today that it has closed a $2.6 million Series B financing round led by Hatteras Venture Partners, a life sciences focused venture firm based in Durham, NC, with participation by existing investors Brook Private Equity Advisors of Boston, MA and Emergent Growth Fund of Gainesville, FL.

October 24, 2007

Durham, NC – Phase Bioscience, Inc., a development stage biotechnology company, announced today that it has successfully raised an additional $5.4 million in Series B financing, bringing the total Series B round to $6.6 million.

June 7, 2007

Drug Discovery and Development Company Focused on Metalloenzymes Closes Series A Round Research Triangle Park , NC – Viamet Pharmaceuticals Inc., a biotechnology company targeting metalloenzymes in the fields of infectious disease, inflammation and oncology, announced today that it has closed a $4 million Series A financing round.

February 9, 2007

DURHAM , NC – Hatteras Venture Partners announced today the first closing of its third venture capital fund, Hatteras Venture Partners III, LP (HVP III). The Fund has secured commitments for $60 million to invest in seed and early-stage companies in biopharmaceuticals, medical devices, diagnostics and related opportunities in human medicine. The ultimate fund size is expected to be $100 million. HVP III may invest in opportunities throughout the country but will focus on forming and leading companies in the southeastern United States, where the level of National Institutes of Health-funded research is high but the availability of early-stage venture capital is limited.